2020
A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma
Nguy S, Du K. A Single Institution Review Of Efficacy Of Neoadjuvant Chemoradiation With Gemcitabine/Abraxane Compared to FOLFIRINOX in Pancreatic Ductal Adenocarcinoma. International Journal Of Radiation Oncology • Biology • Physics 2020, 108: e658-e659. DOI: 10.1016/j.ijrobp.2020.07.1972.Peer-Reviewed Original Research
2017
Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer
Oh P, Du K. Biomarkers that Predict Response to Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer. Current Colorectal Cancer Reports 2017, 13: 276-283. DOI: 10.1007/s11888-017-0376-3.Peer-Reviewed Original ResearchAdvanced rectal cancerRectal cancerNeoadjuvant chemoradiationComplete responsePathologic complete responseStandard of careBowel functionNeoadjuvant therapyOverall survivalTumor responsePotential complicationsChemoradiationBiologic factorsTreatment correlatesCancerSurgeryRecent reportsCurrent literatureBiomarkersResponseComplicationsPatientsTherapyCare
2016
Methylation profiling of locally advanced rectal cancer (LARC): Exploration of potential predictive markers for neoadjuvant chemoradiation (NACR).
Guo S, Melamed J, Eze O, Bowman C, Ahmed S, Moore H, Loomis C, Heguy A, Brody R, Morrison D, Serrano J, Du K, Wu J, Ryan T, Cohen D, Gu P, Goldberg J, Snuderl M, Leichman L, Leichman C. Methylation profiling of locally advanced rectal cancer (LARC): Exploration of potential predictive markers for neoadjuvant chemoradiation (NACR). Journal Of Clinical Oncology 2016, 34: 614-614. DOI: 10.1200/jco.2016.34.4_suppl.614.Peer-Reviewed Original ResearchTotal mesorectal excisionNeoadjuvant chemoradiationLaser capture microdissectionRectal cancerInvasive carcinomaNormal epitheliumNew York University HospitalFuture prospective trialsComplete pathologic responseAdvanced rectal cancerPotential predictive markerOptimal clinical outcomesPathologic responseProspective trialMesorectal excisionClinical outcomesColorectal cancerInflammatory cellsPathologic outcomesPredictive biomarkersPredictive markerUniversity HospitalPathologic resultsH3K27me3 immunohistochemistryClinical cohort
2015
Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer
Bitterman DS, Salgado L, Moore HG, Sanfilippo NJ, Gu P, Hatzaras I, Du KL. Predictors of Complete Response and Disease Recurrence Following Chemoradiation for Rectal Cancer. Frontiers In Oncology 2015, 5: 286. PMID: 26734570, PMCID: PMC4686647, DOI: 10.3389/fonc.2015.00286.Peer-Reviewed Original ResearchDistant metastasis-free survivalDisease-free survivalComplete responseLocoregional controlCarcinoembryonic antigenAnal vergeIndependent predictorsRectal cancerTumor sizeCR groupNode-positive rectal cancerThree-year locoregional controlNode-positive diseaseDistance of tumorNon-operative managementMetastasis-free survivalLong-term outcomesTreatment response evaluationDefinitive chemoradiationRectal patientsNeoadjuvant chemoradiationMost patientsNode positivityOverall survivalSelect patients